Glenn Miller

Title: Glenn Miller: Innovator in Cancer Treatment

Introduction

Glenn Miller is a notable inventor based in Port Washington, NY (US). He has made significant contributions to the field of cancer research through his innovative work. His research focuses on the treatment of cancer using monoclonal antibodies, which has the potential to improve therapeutic outcomes for patients.

Latest Patents

Glenn Miller holds a patent for "Compositions and method for treatment of cancer using monoclonal." This patent highlights the role of cell surface gangliosides in cell growth and differentiation. His findings indicate that G.sub.D3, a disialoganglioside predominantly expressed by neuroectodermal cells, is also present in a subpopulation of immune system cells. The patent details how mouse monoclonal antibodies reacting with G.sub.D3 can stimulate the proliferation of T cells derived from peripheral blood, with the potential for augmentation through various agents.

Career Highlights

Miller is affiliated with the Sloan-Kettering Institute for Cancer Research, where he conducts his research. His work has been instrumental in advancing the understanding of cancer treatment methodologies. He has dedicated his career to exploring innovative approaches to combat cancer, making him a valuable asset in the field.

Collaborations

Throughout his career, Glenn Miller has collaborated with esteemed colleagues such as Alan N. Houghton and Karl Welte. These collaborations have further enriched his research and contributed to the advancement of cancer treatment strategies.

Conclusion

Glenn Miller's contributions to cancer research through his innovative patent and collaborations underscore his commitment to improving patient outcomes. His work exemplifies the importance of innovation in the fight against cancer.